Researchers at the University of Pittsburgh will commence a clinical trial on a vaginal microbicide incorporating the antiretroviral drug tenofovir in pregnant women.

An Australian-developed HIV microbicide gel that has been successful in preventing infection in animal studies is expected enter preliminary human trials in Australia before the end of the year.

The product, VivaGel, is designed to be inserted into the vagina before sex to help prevent HIV infection. It contains a small protein called a dendrimer that is designed to prevent HIV from attaching to and entering cells.